By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TiGenix 

Head Office
Technologielaan 3
Leuven    B - 3001  Belgium
Phone: 32-16-39-60-60 Fax: 32-16-39-60-70


SEARCH JOBS


Industry
Biotechnology






Company News
Takeda (TKPYY) And TiGenix Announce Publication In The Lancet Of 24-Week Results Of The Phase 3 ADMIRE-CD Trial Investigating Cx601 In The Treatment Of Complex Perianal Fistulas In Patients With Crohn's Disease 8/2/2016 6:42:44 AM
Cormorant Asset Management, LLC Notifies 5.81% Shareholding In TiGenix 7/20/2016 9:37:40 AM
TiGenix Reconfirms Its Strategic Focus On Its Allogeneic Stem Cell Platforms 7/5/2016 9:49:00 AM
TiGenix Lands $400 Million+ Crohn's Disease Deal with Pharma Giant Takeda (TKPYY) 7/5/2016 6:09:30 AM
TiGenix Announces Six-Month Phase I/II Results Of Allocsc-01 In Acute Myocardial Infarction 6/20/2016 11:30:00 AM
TiGenix CEO Eduardo Bravo Assumes Leadership Of European Biopharmaceutical Enterprises (EBE) 6/17/2016 8:54:52 AM
TiGenix CEO Eduardo Bravo Assumes Leadership Of European Biopharmaceutical Enterprises (EBE) 6/16/2016 10:54:31 AM
TiGenix Release: Convening Notice To The Annual Shareholders' Meeting To Be Held On 2 June 2016 5/3/2016 8:40:54 AM
TiGenix Selects TFS For The First Clinical Trial To Treat Severe Sepsis With Allogeneic Expanded Adipose-Derived Stem Cells 4/19/2016 9:06:33 AM
TiGenix Presents 24 Week Results Of Its Cx601 Phase III Trial At ECCO 2016 3/18/2016 9:03:35 AM
12345678910...
//-->